Analytical Data
-
基因名
GRHPR
- Application
-
别名
GLXR; glycerate 2 dehydrogenase ; GLYD; Glyoxylate reductase/hydroxypyruvate reductase; Grhpr; GRHPR_HUMAN; OTTHUMP00000021379; OTTHUMP00000021380; OTTHUMP00000046131; PH 2; PH2; Primary hyperoxaluria type 2
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9UBQ7
-
表达区间
1-328aa
-
氨基酸序列
MRPVRLMKVFVTRRIPAEGRVALARAADCEVEQWDSDEPIPAKELERGVAGAHGLLCLLSDHVDKRILDAAGANLKVISTMSVGIDHLALDEIKKRGIRVGYTPDVLTDTTAELAVSLLLTTCRRLPEAIEEVKNGGWTSWKPLWLCGYGLTQSTVGIIGLGRIGQAIARRLKPFGVQRFLYTGRQPRPEEAAEFQAEFVSTPELAAQSDFIVVACSLTPATEGLCNKDFFQKMKETAVFINISRGDVVNQDDLYQALASGKIAAAGLDVTSPEPLPTNHPLLTLKNCVILPHIGSATHRTRNTMSLLAANNLLAGLRGEPMPSELKL
-
分子量
61.82 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The GRHPR (Glyoxylate Reductase/Hydroxypyruvate Reductase) protein plays a crucial role in the metabolic pathways of glyoxylate and hydrogen peroxide, primarily functioning in the liver where it helps convert glyoxylate to glycolate and hydroxypyruvate to glycerate. Deficiencies in GRHPR have been linked to primary hyperoxaluria type II, a genetic disorder characterized by excessive oxalate production, leading to kidney damage and systemic complications. Understanding the structure and function of GRHPR is vital for developing therapeutic strategies for such conditions. Recent studies have concentrated on the recombinant expression of GRHPR, allowing for detailed analysis of its enzymatic properties, structural characteristics, and regulatory mechanisms. This research not only elucidates the enzyme's role in metabolic processes but also provides insights into potential interventions for managing hyperoxaluria and related disorders. By utilizing recombinant DNA technology, researchers can produce large quantities of functional GRHPR, facilitating experiments that explore enzyme kinetics, substrate specificity, and interaction with various cofactors. Moreover, insights gained from these studies could pave the way for gene therapy approaches or the development of small molecule drugs aimed at restoring GRHPR function in affected individuals. Thus, the recombinant GRHPR research represents a promising frontier in understanding metabolic diseases and enhancing therapeutic options for managing disorders associated with oxalate metabolism.
